Citizens raised the firm’s price target on Avalo Therapeutics (AVTX) to $62 from $52 and keeps an Outperform rating on the shares. Avalo Therapeutics reported positive Phase 2 results for abdakibart in hidradenitis suppurativa, demonstrating competitive efficacy and a favorable safety profile, supporting blockbuster potential and strengthening confidence in its clinical and commercial outlook, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Morning News Wrap-Up, 5/6/26: Today’s Biggest Stock Market Stories!
- Why Is Avalo Therapeutics Stock (AVTX) Up Today?
- Julian Harrison Raises AVTX Price Target to $58 on Strong Phase 2 LOTUS Data and Differentiated Safety Profile for Abdakibart
- Avalo Therapeutics Reports Strong Phase 2 Hidradenitis Data
- Avalo Therapeutics announces common stock and warrants offering, no amount given